Search

Your search keyword '"Sarah Atmajoana"' showing total 2 results
Start Over Author "Sarah Atmajoana"
2 results on '"Sarah Atmajoana"'

1. A plasma miRNA-based classifier for small cell lung cancer diagnosis

Author

Michela Saviana, Giulia Romano, Joseph McElroy, Giovanni Nigita, Rosario Distefano, Robin Toft, Federica Calore, Patricia Le, Daniel Del Valle Morales, Sarah Atmajoana, Stephen Deppen, Kai Wang, L. James Lee, Mario Acunzo, and Patrick Nana-Sinkam

Subjects
small cell lung cancer, microRNAs, biomarkers, oncology, classifier, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

IntroductionSmall cell lung cancer (SCLC) is characterized by poor prognosis and challenging diagnosis. Screening in high-risk smokers results in a reduction in lung cancer mortality, however, screening efforts are primarily focused on non-small cell lung cancer (NSCLC). SCLC diagnosis and surveillance remain significant challenges. The aberrant expression of circulating microRNAs (miRNAs/miRs) is reported in many tumors and can provide insights into the pathogenesis of tumor development and progression. Here, we conducted a comprehensive assessment of circulating miRNAs in SCLC with a goal of developing a miRNA-based classifier to assist in SCLC diagnoses.MethodsWe profiled deregulated circulating cell-free miRNAs in the plasma of SCLC patients. We tested selected miRNAs on a training cohort and created a classifier by integrating miRNA expression and patients’ clinical data. Finally, we applied the classifier on a validation dataset.ResultsWe determined that miR-375-3p can discriminate between SCLC and NSCLC patients, and between SCLC and Squamous Cell Carcinoma patients. Moreover, we found that a model comprising miR-375-3p, miR-320b, and miR-144-3p can be integrated with race and age to distinguish metastatic SCLC from a control group.DiscussionThis study proposes a miRNA-based biomarker classifier for SCLC that considers clinical demographics with specific cut offs to inform SCLC diagnosis.

Published
2023
Full Text
View/download PDF

2. Establishing a Cohort and a Biorepository to Identify Biomarkers for Early Detection of Lung Cancer: The Nashville Lung Cancer Screening Trial Cohort

Author

Dhairya A. Lakhani, Chirayu Shah, Sheau-Chiann Chen, Eric L. Grogan, Sophie Jouan, Stephen A. Deppen, Anthony Disher, Luis E. Huerta, Sarah Atmajoana, Khushbu Patel, Alexandra Miller, Hina Shujat, Katrina Brewer, Janelle Wenstrup, Nancy Liu, Rajbir Singh, Heidi Chen, Subodh Nag, Alexis B. Paulson, John T Helton, Kim L. Sandler, Richard D. Fremont, Anel Muterspaugh, Sara L Block, Otis B. Rickman, Melinda C. Aldrich, Rosana Eisenberg, Pierre P. Massion, Sanja L. Antic, Aneri B. Balar, Christine M. Cook, Ronald C. Walker, Gary T. Smith, Bennett A. Landman, Kim Fields, Amy Hinton, and Brandon Winston

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, Lung Neoplasms, business.industry, MEDLINE, Early detection, medicine.disease, Biorepository, Internal medicine, Cancer screening, Cohort, Medicine, Humans, Mass Screening, Prospective Studies, Longitudinal cohort, business, Lung cancer, Tomography, X-Ray Computed, Lung cancer screening, Biomarkers, Early Detection of Cancer, Original Research
Abstract

Rationale: A prospective longitudinal cohort of individuals at high risk of developing lung cancer was established to build a biorepository of carefully annotated biological specimens and low-dose computed tomography (LDCT) chest images for derivation and validation of candidate biomarkers for early detection of lung cancer. Objectives: The goal of this study is to characterize individuals with high risk for lung cancer, accumulating valuable biospecimens and LDCT chest scans longitudinally over 5 years. Methods: Participants 55–80 years of age with a 5-year estimated risk of developing lung cancer >1.5% were recruited and enrolled from clinics at the Vanderbilt University Medical Center, Veteran Affairs Medical Center, and Meharry Medical Center. Individual demographic characteristics were assessed via questionnaire at baseline. Participants underwent an LDCT scan, spirometry, sputum cytology, and research bronchoscopy at the time of enrollment. Participants will be followed yearly for 5 years. Positive LDCT scans are followed-up according to standard of care. The clinical, imaging, and biospecimen data are collected prospectively and stored in a biorepository. Participants are offered smoking cessation counseling at each study visit. Results: A total of 480 participants were enrolled at study baseline and consented to sharing their data and biospecimens for research. Participants are followed with yearly clinic visits to collect imaging data and biospecimens. To date, a total of 19 cancers (13 adenocarcinomas, four squamous cell carcinomas, one large cell neuroendocrine, and one small-cell lung cancer) have been identified. Conclusions: We established a unique prospective cohort of individuals at high risk for lung cancer, enrolled at three institutions, for whom full clinical data, well-annotated LDCT scans, and biospecimens are being collected longitudinally. This repository will allow for the derivation and independent validation of clinical, imaging, and molecular biomarkers of risk for diagnosis of lung cancer. Clinical trial registered with ClinicalTrials.gov (NCT01475500).

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results